| (Values in U.S. Thousands) | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2025 |
| Sales | 0 | 3,550 | 1,430 | 0 | 0 |
| Sales Growth | -100.00% | +148.25% | unch | unch | unch |
| Net Income | -35,810 | -22,670 | 15,800 | 0 | 0 |
| Net Income Growth | -57.96% | -243.48% | unch | unch | unch |
Effector Therapeutics Inc (EFTR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
eFFECTOR Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as STRIs. eFFECTOR Therapeutics Inc., formerly known as Locust Walk Acquisition Corp., is based in SAN DIEGO.
Fiscal Year End Date: 12/31